INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model

Investigational New Drugs

Volumn 28, Issue 1, 2010, Pages 14-19

  Graeser, R ^a,b   Esser, N ^a,b   Unger, H ^a   Fichtner, I ^c   Zhu, A ^d   Unger, C ^a   Kratz, F ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b PROQINASE GMBH   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d Innovive Pharmaceuticals   (United States)

Author keywords

(6 Maleimidocaproyl)hydrazone derivative of doxorubicin; Doxorubicin; Human serum albumin; INNO 206; Prodrug; Tumor models

Indexed keywords

(6 MALEIMIDOCAPROYL)HYDRAZONE DERIVATIVE OF DOXORUBICIN; ADRIMEDAC; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GEMCITABINE; INNO 206; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LUNG SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; HUMANS; HYDRAZONES; INHIBITORY CONCENTRATION 50; MICE; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74149085146     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9208-2     Document Type: Article

References (23)

1. F Kratz A Warnecke B Schmid D-E Chung M Gitzel 2006 Prodrugs of anthracyclines in cancer chemotherapy Curr Med Chem 13 477 523 10.2174/092986706776055751 1:CAS:528:DC%2BD28Xit1Klu7s%3D 16515518
2. F Kratz IA Muller C Ryppa A Warnecke 2008 Prodrug strategies in anticancer chemotherapy ChemMedChem 3 20 53 10.1002/cmdc.200700159 1:CAS:528:DC%2BD1cXlt1KqsrY%3D 17963208
3. TM Allen PR Cullis 2004 Drug delivery systems: entering the mainstream Science 303 1818 1822 10.1126/science.1095833 1:CAS:528:DC%2BD2cXitFehu70%3D 15031496 (Pubitemid 38374867)
4. A Warnecke I Fichtner D Garmann U Jaehde F Kratz 2004 Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs Bioconjug Chem 15 1349 1359 10.1021/bc049829j 1:CAS:528:DC%2BD2cXovVGqtrg%3D 15546202 (Pubitemid 39552025)
5. A Warnecke I Fichtner G Sass F Kratz 2007 Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B Arch Pharm (Weinheim) 340 389 395 10.1002/ardp.200700025 1:CAS:528:DC%2BD2sXpslCgsL8%3D (Pubitemid 47291181)
6. A Warnecke F Kratz 2003 Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy Bioconjug Chem 14 377 387 10.1021/bc0256289 1:CAS:528:DC%2BD3sXhsF2ksLg%3D 12643748 (Pubitemid 36348661)
7. F Kratz A Warnecke K Scheuermann C Stockmar J Schwab P Lazar P Drückes N Esser J Drevs D Rognan C Bissantz C Hinderling G Folkers I Fichtner C Unger 2002 Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J Med Chem 45 5523 5533 10.1021/jm020276c 1:CAS:528:DC%2BD38XosFWhurs%3D 12459020 (Pubitemid 35424970)
8. F Kratz R Muller-Driver I Hofmann J Drevs C Unger 2000 A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy J Med Chem 43 1253 1256 10.1021/jm9905864 1:CAS:528:DC%2BD3cXhsFyhtLw%3D 10753462 (Pubitemid 30212566)
9. AM Mansour J Drevs N Esser FM Hamada OA Badary C Unger I Fichtner F Kratz 2003 A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 Cancer Res 63 4062 4066 1:CAS:528:DC%2BD3sXlsFOju7k%3D 12874007
10. R Graeser DE Chung N Esser S Moor C Schachtele C Unger F Kratz 2008 Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP) Int J Cancer 122 1145 1154 10.1002/ijc.23050 1:CAS:528:DC%2BD1cXhslGgs7o%3D 17973264 (Pubitemid 351222535)
11. Kratz, F (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132:171-183
12. F Kratz U Beyer 1998 Serum proteins as drug carriers of anticancer agents: a review Drug Deliv 5 281 299 10.3109/10717549809065759 1:CAS:528:DyaK1MXntV2hsg%3D%3D 19569996
13. F Kratz 2007 DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin Investig Drugs 16 855 866 10.1517/13543784.16.6.855 1:CAS:528:DC%2BD2sXltlOju7Y%3D 17501697 (Pubitemid 46882358)
14. F Kratz G Ehling HM Kauffmann C Unger 2007 Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin Hum Exp Toxicol 26 19 35 10.1177/0960327107073825 1:CAS:528:DC%2BD2sXjtFyqsLk%3D 17334177 (Pubitemid 46262744)
15. D Lebrecht A Geist UP Ketelsen J Haberstroh B Setzer F Kratz UA Walker 2007 The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage Int J Cancer 120 927 934 10.1002/ijc.22409 1:CAS:528:DC%2BD2sXht1elt7c%3D 17131338 (Pubitemid 46175416)
16. C Unger B Haring M Medinger J Drevs S Steinbild F Kratz K Mross 2007 Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin Clin Cancer Res 13 4858 4866 10.1158/1078-0432.CCR-06- 2776 1:CAS:528:DC%2BD2sXptVGmtL4%3D 17699865 (Pubitemid 47294793)
17. Graeser R, Bornmann C, Esser N, Ziroli V, Jantscheff P, Unger C, Hopt UT, Schaechtele C, von Dobschuetz E, Massing U (2008) Anti-metastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas (in press)
18. F Kratz T Roth I Fichtner P Schumacher HH Fiebig C Unger 2000 In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model J Drug Target 8 305 318 10.3109/10611860008997908 1:CAS:528: DC%2BD3MXhsFSqtbw%3D 11328658
19. PA Trail D Willner SJ Lasch AJ Henderson RS Greenfield D King ME Zoeckler GR Braslawsky 1992 Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models Cancer Res 52 5693 5700 1:CAS:528:DyaK38XmsVGisLs%3D 1382845
20. S Noble KL Goa 1997 Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer Drugs 54 447 472 10.2165/00003495-199754030-00009 1:CAS:528:DyaK2sXlvFelt7c%3D 9279506
21. HG Hotz HA Reber B Hotz T Yu T Foitzik HJ Buhr G Cortina OJ Hines 2003 An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer Pancreas 26 89 98 10.1097/00006676-200305000-00020
22. M Edinger TJ Sweeney AA Tucker AB Olomu RS Negrin CH Contag 1999 Noninvasive assessment of tumor cell proliferation in animal models Neoplasia 1 303 310 10.1038/sj.neo.7900048 1:STN:280:DC%2BD3cvhvFKltw%3D%3D 10935484
23. H Maeda J Wu T Sawa Y Matsumura K Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 271 284 10.1016/S0168-3659(99)00248-5 1:CAS:528:DC%2BD3cXhtl2qsLo%3D 10699287 (Pubitemid 30122932)